Abstract
Aurora kinases are cell cycle regulated serine/threonine kinases that have been linked to cancer. Compound 1 was identified as a potent Aurora inhibitor but lacked oral bioavailability. Optimization of 1 led to the discovery of a series of fluoroamine and deuterated analogues, exemplified by compound 25, with an improved pharmacokinetic profile. We found that blocking oxidative metabolism at the benzylic position and decreasing the basicity of the amine are important to obtaining compounds with good biological profiles and oral bioavailability.
MeSH terms
-
Administration, Oral
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Aurora Kinases
-
Biological Availability
-
Cell Line, Tumor
-
Deuterium
-
Dogs
-
Drug Screening Assays, Antitumor
-
Fluorine*
-
Histones / metabolism
-
Humans
-
Imidazoles / chemical synthesis*
-
Imidazoles / pharmacokinetics
-
Imidazoles / pharmacology
-
Macaca fascicularis
-
Mice
-
Mice, Nude
-
Neoplasm Transplantation
-
Phosphorylation
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Pyrazines / chemical synthesis*
-
Pyrazines / pharmacokinetics
-
Pyrazines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Structure-Activity Relationship
-
Transplantation, Heterologous
Substances
-
Antineoplastic Agents
-
Histones
-
Imidazoles
-
Pyrazines
-
Fluorine
-
Deuterium
-
Aurora Kinases
-
Protein Serine-Threonine Kinases